All In Biotech

Drug Trial Radar · NCT05150392

An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization

An Open-labelled Clinical Trial,to Evaluate the Immunity Persistence of the Single-dose Primary Immunization of Live Attenuated Varicella Vaccine on Different Time Points,and the Safety and Immunogenicity After the Booster Immunization

Last checked: Nov 19, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,193

Actual

Start

Jul 11, 2018

Primary completion

Aug 11, 2018

Study completion Aug 14, 2020

Sponsor

Sponsor type
Industry
First posted
Dec 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 6 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-labelled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of the single-dose primary immunization of live attenuated varicella vaccine on different time points ,and the safety and immunogenicity after the booster immunization

Conditions

  • Varicella

Interventions

  • Investigational live attenuated varicella vaccineBiological

    The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immunogenicity index-seroconversion rate of antibodyTime frame: 1 year after primary immunization
  2. Immunogenicity index-seroconversion rate of antibodyTime frame: 2 years after primary immunization
  3. Immunogenicity index-seroconversion rate of antibodyTime frame: 3 years after primary immunization
  4. Immunogenicity index-Seroconversion rate of antibodyTime frame: 30 days after booster immunization
  5. Immunogenicity index-seropositivity rate of antibodyTime frame: 30 days after booster immunization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangfu County Center for Disease Control and Prevention

    Kaifeng, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.